AbbVie Inc vs Strategy Inc. — how do they compare? AbbVie Inc trades at $250.55 (market cap $438.19B), while Strategy Inc. trades at $95.94 (market cap $38.33B). The key difference: AbbVie Inc is far larger — about 11.4× Strategy Inc.'s market cap, and AbbVie Inc pays a 2.79% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| ABBV | MSTR | |
|---|---|---|
Market Cap | $438.19B | $38.33B |
Sector | Health | Technology |
52-Week High | $263.58 | $400.25 |
52-Week Low | $197.38 | $82.31 |
Enterprise Value | $502.45B | $57.09B |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $250.50, up 1.81% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and robust revenue growth, driven by Skyrizi and Rinvoq, highlight fundamental strength. The stock is supported by a 70.73% buy rating from analysts and a consensus price target of $281.33, with positive news flow from clinical trial results and institutional buying.
The outlook remains positive with earnings growth and dividend sustainability, though risks include patent cliffs in the 2030s and competitive pressures. Valuation metrics like a P/E of 70.05 suggest premium pricing, but operational cash flow of $19.03B in 2025 supports continued investment and shareholder returns.
MSTR trades at $100.01, up 3.26% today, with a bullish technical signal despite recent earnings misses. The company reported Q2 2026 EPS of -$24.45 versus -$2.19 expected, continuing a trend of negative profitability. Analyst consensus remains positive with a $210 price target, though fundamentals show significant challenges including a negative net income margin of -6,102.96% and substantial Bitcoin-related investment outflows.
The outlook is mixed: strong analyst support suggests upside potential, but fundamental weaknesses and persistent earnings misses pose substantial risks. Investment opportunity exists if the company can leverage its cash position for growth, while risks include continued operational losses and dependence on Bitcoin market performance.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →